Shares of Lipocine Inc. (NASDAQ:LPCN – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.07 and traded as low as $3.50. Lipocine shares last traded at $3.99, with a volume of 470,538 shares traded.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on Lipocine in a research report on Saturday. They set a “hold” rating for the company.
Get Our Latest Report on Lipocine
Lipocine Stock Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.35 million.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC boosted its stake in shares of Lipocine Inc. (NASDAQ:LPCN – Free Report) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by hedge funds and other institutional investors.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Further Reading
- Five stocks we like better than Lipocine
- What is the Euro STOXX 50 Index?
- Meta’s 5 Key Pillars for AI Growth—Zuckerberg’s Bold Vision
- Why Invest in 5G? How to Invest in 5G Stocks
- Retail Investors Are Betting Big on Rocket Lab—Should You Too?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
